Sulfacil 200 mg/ml picături oftalmice, soluţie Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sulfacil 200 mg/ml picături oftalmice, soluţie

farmak sa - sulfacetamidum natricum - picături oftalmice, soluţie - 200 mg/ml

Ibuprofen 200 mg capsule moi Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ibuprofen 200 mg capsule moi

apotex inc. - ibuprofenum - capsule moi - 200 mg

Ibuprofen 400 mg capsule moi Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ibuprofen 400 mg capsule moi

apotex inc. - ibuprofenum - capsule moi - 400 mg

Rhinobos 160 mg + 1 mg + 2,5 mg sirop Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rhinobos 160 mg + 1 mg + 2,5 mg sirop

bosnalijek, pharmaceutical and chemical industry jsc - paracetamolum + chlorphenaminum + phenylephrinum - sirop - 160 mg + 1 mg + 2,5 mg

Rhinobos 325 mg + 2 mg + 5 mg comprimate Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rhinobos 325 mg + 2 mg + 5 mg comprimate

bosnalijek, pharmaceutical and chemical industry jsc - paracetamolum + chlorphenaminum + phenylephrinum - comprimate - 325 mg + 2 mg + 5 mg

Rhinostop 251 mg + 61,2 mg + 2,54 mg comprimate Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rhinostop 251 mg + 61,2 mg + 2,54 mg comprimate

bosnalijek, pharmaceutical and chemical industry jsc - paracetamolum + pseudoephedrinum + chlorphenaminum - comprimate - 251 mg + 61,2 mg + 2,54 mg

Rhinostop 101 mg + 20,2 mg + 1,01 mg/5 ml sirop Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rhinostop 101 mg + 20,2 mg + 1,01 mg/5 ml sirop

bosnalijek, pharmaceutical and chemical industry jsc - paracetamolum + pseudoephedrinum + chlorphenaminum - sirop - 101 mg + 20,2 mg + 1,01 mg/5 ml

Imatinib Actavis Европска Унија - Румунски - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

Gazyva 1000 mg concentrat pentru soluţie perfuzabilă Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gazyva 1000 mg concentrat pentru soluţie perfuzabilă

f.hoffmann-la roche ltd - obinutuzumabum - concentrat pentru soluţie perfuzabilă - 1000 mg

Hepatoprotect comprimate 150 mg Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

hepatoprotect comprimate 150 mg

biofarm sa, sc - silibinum - comprimate - 150 mg